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Pipradrol HCl was developed in the early 1950s by the 
Wm. S. Merre ll Co., Cincinnati, Ohio, as a n ew chemi cal -
type s timul ant. Designate d by the company as MDR-108, it 
was shown to induce c h anges in the activity of laboratory 
animals, specifically an acce l e ration of reaction time to 
environmental s timuli. Small doses were admi nister e d to 
pigs, mice, guinea pigs, rats a nd rabbits and wer e observed 
to induce ext r e mely r ap id but highly coordinated movements 
such as lickin g , c h ewin g , eat ing, drinking and scratch ing . 
These observa tions c losely resembled those seen by the 
administration of amph e t amine ( 1) . 
Pipradrol HCL i s alpha-(pipe ridyl)ben zh ydr o l hydr o-
c hloride. The hydroch l o ride salt is a white o dorless powder 
with a slightly bitter taste. One part dissolves in about 
60 parts of hot wat e r. Pipradrol is a lso k nown by trade 
n a mes s u c h as Alertol, Gadexyl, Ceptidrol, Meratoni c a nd 
-1-
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Pipradro l Amphetamine 
Considering the similarity between the action of pip-
radrol and amphetamine on laboratory animals, it was ques-
tioned as to whether or not the stereochemical e na ntiomers 
of pipradrol would also have differe nt pharmacological 
actions . Therefore, Portoghese and co-workers (3) con-
ducted studi es on rat l ocomotor activity using enantiomers 
of pipradrol synthesized from (R)- a nd (S)- pipecolic acid. 
I t was found t h at all of the central stimulant activity was 
due to t h e (R)- pipradrol enantiomer while the more active 
enantiomer of amphetamine possessed the opposite configura-
tion . Becaus e o f these steric differences in activity, it 
was suggested that these compounds may be acting on dif-
ferent receptors in the central nervous system. 
The administration of lethal doses of pipradrol intra-
venous ly to mice, rats , guinea pigs and rabbits caused 
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tremors and convulsions with death occurring during the con-
vulsive stage due to respiratory failure. Lethal doses 
given orally to dogs caused an increase in motor activity 
(circling and rolling) with the animals becoming less co-
ordinated but rarely experiencing convulsions . Death occur-
red suddenly during the hyperactivity stage. 
Early observations in dogs given pipradrol showed it 
to differ behaviorally from amphetamine in that the animals 
did not become irritable and remained amenable to handling 
whereas animals treated with amphetamines were easily ag-
gravated (1). With these observations, pipradrol became 
classified pharmacologically as a psychomotor stimulant. 
Psychomotor stimulants are known to increase locomotor 
activity and to induce stereotyped behavior (4). Loco-
motor activity in rats can be measured by means of a photo-
cell cage utilizing two parallel photocell beams directed 
across the long axis of the cage. The number of inter-
ruptions of the photocell beam indicates the de gree of 
activity of the test animals. Stereotypic behavior in 
rats is usually manifested by continuous sniffing, licking 
or biting , grinding of the jaws, grooming, rearing and 
occasionally by backward locomotion (5) . Sahakian et al. 
(6) postulated that these two behaviors might be mediated 
by different mechanisms. 
Psychomotor stimulation can also facilitate operant 







of the brain (7-9). Therefore, it has been suggested that 
the increase in behavioral activity produced by psycho-
motor stimulants results from an increase in the value of 
the rewarding stimuli. This effect may be mediated by the 
potentiation of a brain reinforcement mechanism (10) . 
Robbins (11) believed that this "reward enhancing" property 
and the stereotypic effects of psychomotor stimulants could 
arise from a common mechanism. 
Pipradrol, when given to rats, has been shown to cause 
an increase in both locomotor activity and stereotypic be-
havior (12, 13). The concept of the facilitation of con-
ditioned reinforcement may be thought of as a sensitization 
of the neural systems involved in the processing of rewards. 
This would result in increased effectiveness of the 
stimuli controlling behavior. Pipradrol may be viewed, 
therefore, as a drug which serves to either facilitate or 
inhibit the various motor responses that make up the total 
behavior of the animal. 
Clinical Considerations 
Pipradrol has been used clinically in treating condi-
tions of mild to moderately severe mood disorders of reac-
tive depression (14). It has been used to elevate mood and 
to alleviate psychomotor retardation, attention defect, loss 
of interest, and withdrawal from social intercourse (15). 
The above conditions may be construed as situations in which 
a lack of sufficient reward exists for the patient to 
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- function at normal behavioral l e vel s . In the geriatric 
patient, pipradrol has also been us e d as an activity booster. 
When administered in a vitamin-containing tonic, it has 
the effect of making simple tasks such as gardening, shop-
ping and other household activities much more pleasurable, 
thus increasing the quality and productivity of life for 
the elderly patient (16). The effectiveness of pipradrol 
in alleviating these conditions may be attributed to its 
ability to increase the effectiveness of the conditioned 
reinforcer. This property may also be responsible for it s 
decrease in clinical utility. When the disorder is not 
merely a depressed emotional state but associated with un-
desirable behavioral patterns, the effect of pipradrol may 
be to aggravate the condition . Thus the mani c patient be-
comes more manic, the agitated patient becomes more agitated 
and the anxious patient becomes more anxious (15) . 
With the marketing of more effective antidepressant 
drugs in r ecent years, pipradrol has fallen from clinical 
favor and is no longer commercially available for use . In 
rece nt clinical trials (double-blind, placebo-controlled 
studies), physicians reported no indication of any 
- -- superiority of pipradrol over placebo in t r eatin g depres-
sion . On the other hand, pipradrol caused significantly 
more anorexia and we i ght loss than placebo (17). 
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Temperature Regulation 
In the homeothermic or "warm-blooded" animal, it is 
essential that body temperature be maintained within a 
very narrow range to insure optimal conditions for en-
zymatic reactions. Normal body temperature is maintained 
by mechanisms involving either heat production or heat 
loss. 
One major source of heat production is derived from 
skeletal muscle in processes such as locomotion, manual 
work and shivering. In some animal species and in infants 
(but not adult humans), a considerable source of heat may 
be derived from the metabolism of a special type of fat 
l ocated around the scapulas a nd called "brown fat." 
The chief means by which heat loss occurs involves the 
radiation or conduction of body heat to the surrounding 
environment . These processes utilize the dilation of cutan-
eous blood vessels channeling warmer blood from the inte-
rior of the body to the s urface thus allowing dissipation 
of heat to occur. For this process to be effective, it is 
necessary that the environmental temperature be cooler 
than the body temperature. Heat l oss is also mediated by 
the vaporization of sweat. In those animals that do not 
sweat, respiration becomes an important means of heat 
loss. In this instance, respiration has the effect of 
vaporizing water in the respiratory passages, nasal sinuses 





The r egulatio n of body temperature is a very complex 
phenomenon most likely involving the integration of various 
reflex neuronal pathways and neurotransmitters . It has been 
well documented that these thermoregulatory processes are 
co- ordinated in t h e central nervous system at the level of 
the hypothalamus (19). The nature of the neurotransmitters 
involved appears to vary from species to species . 
In cats, dogs and monkeys, the intracerebroventricular 
(I.C.V.) administration of norepi nephrine produces hypo-
thermia (20, 21). In rats, the response was dose-dependent 
with t he smaller doses r esult i ng in hyperthermia a nd the 
larger doses producing a pronounced hypothermia (22). In 
both sheep a nd rabbits, I.C.V. norepinephrine resulted in 
hyperthermia (23). 
Thermotropic studies with the neurotransmitter dopamine 
a l so showed a species variation i n its thermic response. 
Dopamine was shown to cause hypothermia when given I.C.V. 
to cats, mice, rats, pigeons, hens,goats and sheep (24- 30). 
However, in rabbits dopamine I.C.V. resulted in a delayed 
hyperthermia which was attr ibuted to its probab l e conver-
sion to norepinephrine (31) . 
Species variation has a l so been shown wit h serotonin 
or 5-hydroxytryptamine (5-HT). I.C.V. a dministration raises 
the body temper ature in cats, dogs and monkeys (32). In 
the rabbit, there are inconsistent reports regarding the 
nature of the thermic response -- ranging from a weak and 
= 
8 
inconsistent hypothermia (32), to a pronounced hypothermia 
(30), to an initial fall followed by a rise in body tempera-
ture (33) . The administration of various drugs thought to 
be 5- HT agonists resulted in a hyperthermic effect which 
was blocked by 5-HT antagonists (34). In goats and oxen, 
the I.C.V. dosage of 5- HT produced a pronounced hypothermic 
effect (23, 35, 36) . 
Histamine has been recognized as a neurotransmitter 
(37) and studies have been conducted to determine its role 
in central thermoregulation. Rats given I .C.V. histamine 
(as well as the H2-receptor agonists dimaprit and impromide) 
show a rise in body temperature wh ich can be blocked by the 
H2-receptor blocker cimetidine (38) . Other studies have 
been conducted showing that the administration I . C . V. of 
histamine to rats will produce hyperthe rmia rather than 
hypothermia (39). However, more rece nt work by Dhawan (40) 
has indicated a dose-dependent response to histamine in 
rats with the lower dose resulting in hyperthermia and the 
higher dose s in hypothermia . Central histamine (H2- re-
ceptor) activity has also been shown to be associated with 
the administration of tne antihypertensive drug clonidine 
(41). Intraperitoneal injection of clonidine in rats re-
sults in a significant decrease in body temperature . This 
effect was attenuated by the I .C . V. injection of the alpha-
adrenergic blocker phentolamine and also by the I.C . V . ad-
ministration of cimetidine indicating involvement of both 
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adrenergic and histaminergic mechanisms in t he hypothermic 
response to clonidine (42). 
Hypothalamic cholinergic mechanisms have been associ-
ated with the control of body temperature in rats (43), 
sheep, goats, rabbits (44), monkeys and cats (45). While 
earlier works of Bligh et al. (44) and Cooper et al. (23) 
failed to show any thermal effect of I.C . V. acetylcholine 
in the rabbit, a more recent study by Tangri and co-workers 
(46) did show a significant hyperthermic response to 
acetylcholine when administered I . C.V. to conscious rabbits. 
In this study, evidence for both nicotinic and muscarinic 
components of acetylcholine was observed to be associated 
with thermoregulation. The hyperthermic r esponse to 
norepinephrine was reporte d to be mediated by nicotini c re-
ceptors and the hypothermic response to 5-HT receptors. It 
was also suggested that the hyperthe rmic adrenergic r esponse 
was related to a "cold-sensitive" mechanism and the hypo-
the rmic serotonergic response related to a "heat sensitive" 
mechanism. Other studies also have shown evidence indicating 
monoaminerg ic and cholinergic mechanisms of thermoregula-
tion in the monkey (47) and noradre naline and 5-HT inter-
action on thermoregulation in the rat (48) . 
Statement of the Problem 
Since pipradrol in this laboratory consistently has 
been shown to e levate the core t e mpe rature of unanesthetized 
rabbits, it was thought possible to study the mechanisms 
of this thermotropic response (presumably mediated via 
the central nerous system) by administering before the 
pipradrol certain pharmacologic agents for which t he 
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central mechanisms of action are reasonably well defined. 
The refore, an agent blocking one of the pipradrol mechanisms 
should lower core temperature . Since the behavioral re-
sponses of pipradrol are distinctive in the rabbit and 
closely r esemble those seen with amphetamine, this study 
also was set up to observe (but not quantitate) the effect 
of the test drugs on the behavioral parameters normally 
seen in the rabbit with pipradrol alone . 
Ha loperidol is generally considered to be a dopamine 
receptor blocker. In the rabbit, haloperidol has been r e-
ported to inhibit the hype rthe rmic response to dopamine 
given I.C.V. (49) and inhibit apomorpine- and amphetamine-
induced hyperthermia which i s thought to b e mediated by 
dopaminergic mechanisms (50) . Pimozide, a selective dop-
amine receptor antagonist has also been shown to block the 
dopamine- mediated hyperthermia seen with apomorphine (51). 
The invo lveme nt of a lpha-adrene r g i c receptors in t he 
central thermoregulatory process has been clearly shown to 
be present in the rabbit (31), a nd the alpha- adrenergic 
blocker phenoxybenzamine has been reported to block the 
hyperthermic response to I.C .V. norepinephrine in this 
a nimal (46) . The present study will also invest i gate two 
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other alpha-blockers: chlorpromazine a nd HEAT . Chlorproma-
zine is not very specific since it has also been shown to 
possess significant a ntihistaminic, anticholinergic and 
antidopaminergic properties (52). HEAT (2- [beta-(4- hydroxy-
phenyl)ethylaminomethyl]-tetralone) has been reported to 
be an effective alpha- adrenergic receptor blocker comparable 
t o chlorpr omazine in its ability to block the central r e -
spon se to norepinephrine . However, it also has very weak 
antagonistic properties for central dopamine receptors 
(stated to be 500 times les s potent than haloperidol in 
blocking apomorpine r esponses) (53). 
The medi ation of hyperthe rmia in r abbits also has been 
associated with seroto nin (5- HT) (34) . The 5-HT receptor 
blockers cypr oheptadin e and c inanserin have been shown to 
antagonize the hyperthermic effect of fenfluramine whic h 
is r eported to act through 5-HT mechanisms (54). Cypro-
heptadine also has significant antihistaminic effects and 
some anticholinergic capacity in addition t o i ts anti-
serotonin activity. 
Dhawan a nd Dua (31) have s ugges t ed that histamine 
may be involved in the thermoregulatory process seen in 
certain species o f r ats; therefore, the present study will 
invest igate the effects of diphe nhydramine, a potent 
inhibito r of H1 histamine r eceptors . Diphenhydramine 
also possesses significant anticholinergic capacity (55). 
Ta ngri et al. (46) have reported a possible c ho linergic 
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mechanism in the rabbit for the control of body temperature; 
therefore, the present study will investigate atropine, an 
agent highly selective for muscarinic receptors (55). 
The work of Dhawan and Dua (31) in the rabbit failed 
to show a role for the beta- adrenergic receptors in the 
response to I.C . V. administered norepinephrine; however, 
there is evidence that, in rats, body temperature regula-
tion is involved with beta-adrenergic receptors. In higher 
doses, the I.C.V. injection of norepinephrine can produce 
a dose-dependent thermic response with the hyperthermia 
being blocked by the beta-adrenergic receptor blocker pro-
pranolol (56) . 
In the present study, the influence of various drug 
pretreatments will be investigated in the rabbit in an at-
tempt to (~) define the pharmacological mechanism of action 
of pipradrol in its mediation of hyperthermia and (Q) ob-
serve the effects of these pretreatments on the behavioral 
effect of pipradrol. Although pipradrol is no longer 
of clinical utility, it is hoped that the results of this 
study may provide more information for its use in future 
studies as a pharmacological tool . 
MATERIALS AND METHODS 
Male New Zealand rabbits (Fredrick's Rabbitry, Modesto, 
California) weighing between 2.0 and 3.0 kg were used for 
this study and housed in an animal room with a controlled 
0 0 temperature of between 21 C and 23 C. The animals were 
allowed to acclimate with free access to food and water 
for a period of not less than 7 days prior to experi-
mentation . On the day of the experiment, the animals were 
taken off food and restrained in wooden stanchions (57) 
for a conditioning period of at least 2 hours or until 
body temperature stabilized. Animals with a temperature 
0 of greater than 40 C were not used. 
Colonic temperatures of all animals were measured by 
means of a thermistor probe (Yellow Springs Instruments 
Model 401) and recorded continuously on a Hone ywell auto-
matic recorder. The thermistor probles were inserted 
rectally to a depth of 15 em and sec ured to the base of 
-13-
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the tail by adhesive tape. The animals were allowed water 
throughout the conditioning and recording sess i ons. 
The following drugs were used in these experiments: 
pipradrol HCl (Merrell); c hlorpromazine HCl (Smith Kline 
a nd French); pimozide (McNeil); phenoxybenzamine HCl (Smith 
Kline and French); 2-[beta-(4-hydroxyphenyl)-ethylamino-
methyl] tetralone (HEAT) (Merck); pentobarbital Na (Abbott); 
clonidine HCl (Boehri nger-Ingel heim); cinanserin HCl (Squibb); 
cyproheptadine HCl (Merck Sharp a nd Dohme); apomorphine HCl 
(Merck Sharp and Dohme) and haloperidol (McNeil). Aqueous 
solutions of the above were used with the exception of 
haloperidol and chlorpromzaine HCl which came as pre-
prepared solut i ons. Pimozi de required acidification with 
glacial acetic acid for solubility. Drug so lutions were 
administered into the marginal ear vein except for pimozide 
which was g iven intraperitoneally and HEAT which was given 
both intrave nously and intracere brove ntricularly. Pre-
treatment times were 30 minutes with t he exception of 
phenoxybenzamine HCl, pimozide and cinanserin HCl (given 
60 minutes prior to the experime nt) and HEAT (given 15 
minutes intracere brovent ricularly prior to the experime nt). 
HEAT was administered into the lateral ventricle 
in the following manner. ~venty-four hours prior to the 
experiment, the animals to be used were anesthesized with 
pentobarbital Na (40 mgfkg ) intravenous ly a nd r estra ine d 
i n open wooden stanchions . Following the loss of the corneal 
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reflex, the area on the top of the head between the ears 
and eyes was shaved using electric clippers. A 2-cm incision 
was made midline exposing the bregma. Using a dental drill, 
a hole the size of a 25-ga~ge needle was drilled through 
the skull at a point 2 mm lateral to the sagittal suture 
and 2 mm posterior to the coronal suture (33, 58). The 
incision was closed with a wound clip and the animals given 
penicillin 600,000 units (Wyeth) intramuscularly and allowed 
to recover. After 24 hours, these animals were again re-
strained in wooden stanchions and colonic temperatures re-
corded for at least 2 hours. Animals with temperatures 
greater than 40° C were sacrificed because of possibl e sys-
temic infection. The incision was then reopened and the 
area cleansed with sterile normal saline . HEAT dissolved 
in sterile normal saline was administered by means of a 
microburet and 3-ml syringe calibrated to give a precise 
volume. The volume was delivered through PE-20 tubing with 
a 5/8-inch, 26-gauge needle attached. The needle was in-
serted into the skull to a depth of 6 mm. A plastic disc 
was fixed to the needle 6 mm from the tip of the bevel and 
this assured the proper depth for implantation as well as 
stabilizing t h e inserted needle in a perpendicular manner. 
The drug was admini stered over a period of 1 minute at a 
fixed total volume of 50 ~l. At the conclusion of the 
experiment, 50 ~l of 2% gentian violet was injected in 
the same manner and the animals were sacrificed. Examination 
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of the lateral ventricles was conducted to note placement 
of the injected dye. 
Tabular values are expressed as t he arithmetic mean 
(Tables I through VI) +one standard error of the mean (SEM). 
Areas-under-the-curve for the response versus time data 
were calculated as shown in Appendix A. Test for signifi -
cance between test groups was ver i fied using Dunnett's t 
test or Student's t test adapted to the Burroughs 6700 
computer by Namba (59). Sample printout of the program 
is shown in Appendix B. 
RESULTS 
The intrave no us (I.V.) a dministr at ion o f pipra drol HCl 
pro duced a dose-de p e nde nt inc r ease in the co l o ni c bo d y t em-
p e rature o f rabbit s (Figure I, Ta ble I) . At 10.0 mg jkg 
I . V., two of t he four test a n i ma l s ha d t o b e sacrif i ced d u e 
to a b od y tempe r ature in e xcess of 44° C . Behavior a l ef-
fects wer e asses sed o n a n a ll-o r-no ne bas i s. An increase 
in l ocomotor a ctivity was o bserve d co ns i s t i ng o f occas i onal 
vocalization a nd excessi ve l eg- t hump ing epi sodes . Mydriasis 
a nd a n i n c r ease i n r esp i ratory r ate wer e a l so o bser ve d as 
we ll as a high i nc ide n ce o f compul sive g nawing. Behav i o r a l 
effects in this a nd s ubsequent t esti ng were not strict l y 
qua n titat ed , so s uc h comme nt s mus t b e r egarded as s ub ject ive 
o b ser vatio ns . 
Eff ec t s of P i p radro l in Rabbits Pret r eat e d with Chlorp r o mazine. 
The a dministratio n of c hlo r p r o mazine HCl I. V . 0.5 mgjkg 
-17-
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30 minutes prior to pipradrol HCl 5.0 mgjkg I.V . (Figure 2, 
Table I), resulted in a significant (~ < 0 . 05) reduction in 
the hyperthermic effect of pipradrol as measured by area-
under-the-curve data (Table I V) . A decrease in the loco-
motor activity was observed with no apparent change in the 
incidence of compulsive gnawin g. 
Effects of Pipradrol in Rabbits Pretreated with Dopamine 
Receptor Blockers. 
Haloperidol 0.5 mgjkg I.V . given 30 minu tes prior to 
pipradrol I.V. 5.0 mg/kg (Figure 3, Table I) failed to 
antagonize t he hyperthermic effect. The area-under-the-
c urve data (Table IV) showed the two curves to be not 
signi ficantly different (~ > 0 . 05). However, haloperidol 
at thi s dose appeared to reduce the incidence of compul-
sive gnawin g. Pimozide 4 . 0 mgjkg intraperitoneally ( I.P. ) 
60 minutes prior to pipradrol 5.0 mg/kg I.V. (Figure 4, 
Table I) a l so failed to significantly (P > 0 . 05) block the 
hyperthermic response of pipradrol (Table IV). Unlike 
haloperidol, pimozide did not appear to reduce the incidence 
of compulsive gnawi ng . 
Ef f ect of Pipradrol in Rabbits Pretreated wit h Alpha 
Adrenergic Receptor Blockers. 
The I.V. admin istration of phenoxybenzamine HCl 1.0 
mgfkg 60 minutes prior to pipradrol 5.0 mgjkg I.V. (Figure 5, 
Table I) resulted in a significant (~ < 0 . 05) attenuation of 
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the hyperthermia seen with pipradrol (Table IV). The pre-
treatment with HEAT 0.125 mgjkg I.V. 30 minutes prior to 
pipradrol 5.0 mgjkg I.V. (Figure 6) also showed a signifi-
cant reduction in the hyperthermia of pipradrol (P < 0.05) 
(Tables I and IV). Compulsive gnawing was not noticeably 
affected by phenoxybenzamine but appeared potentiated by 
HEAT. HEAT at a dose of 0.25 mgjkg given I.V. 30 minutes 
prior to pipradrol 5.0 mgjkg I.V. (Table I) also signifi-
cantly reduced the hyperthermic effect CE < 0.05) of 
pipradrol (Table IV). The animals given HEAT s howed a de -
crease in locomotor activity which appeared to be dose-
dependent with the higher dose of HEAT at 0 . 25 mgjkg re-
sulting in prostration of many of the animals . 
The intracerebroventricular (I.C.V.) administration of 
HEAT 0.15 mg 15 minutes prior to pipradrol 5 . 0 mgjkg I.V. 
(Figure 7) resulted in a significant CE < 0.05) attenuation 
in the hyperthermic response to pipradrol (Tables II and 
V) . HEAT I.C.V. 0.15 mg alone produced a slight decrease 
in the colonic body temperature which was significantly 
CR < 0.05) different from the saline c ontrol (Tables II and 
V) . The de gree of increased locomotor activity due to 
pipradrol was observed to be decreased with the administra-
tion of HEAT I . C.V. in a manner similar to the administra-





Effects of Pipradrol in Rabbits Pretreated with Serotonin 
Receptor Blockers. 
Cinanserin HCl 5.0 mgfkg I.V. given 60 minutes prior 
to pipradrol HCl 5.0 mg/kg I.V. (Figure 8) did not signifi-
cantly block CE > 0.05) the hyperthermic response of pip-
radrol (Tables I and IV). The I.V. pretreatment of cypro-
heptadine HCl 5.0 mgfkg (Figure 9) did not block the 
hyperthermic effect of pipradrol 5.0 mgjkg I.V.; in fact, 
the effect seen was a significant CE < 0.05) potentiation 
of the hyperthermic response to pipradrol (Table IV). 
Effect of Pipradrol in Rabbits Pretreated with Histamine 
Receptor Blockers. 
While cyproheptadine has significant affinity for both 
serotonin and histamine receptors and some affinity for 
muscarinic receptors, diphenhydramine has affinity for only 
histaminic receptors (and to a lesser extent cholinergic 
receptors). Diphenhydramine HCl 6 .0 mgjkg I.V. give n 30 
minutes prior to the I.V. administration of pipradrol 
5.0 mgfkg (Figure 10) was ineffective CE > 0 .05) in blocking 
the hyperthermia induced by pipradrol (Table I). The effect 
appeared to be potentiated but this effect was not shown 
to be statistically significant (£ > 0.05) (Table IV). 





Effects of Pipradrol in Rabbits Pretreated with Cholinergic 
Receptor Blockers. 
Atropine has l ittle to no affinity for serotonergic 
and histaminergic receptors, but has high affinity for mus-
carinic acetylcholine receptors (and to a lesser extent 
nicotinic acetylcholine receptors) . Atropine so4 2 . 0 mgjkg 
given I.V. 30 minutes prior to pipradrol HCl 5.0 mgjkg 
(Figure 11) was shown to significantly potentiate the hyper-
thermic effect of pipradrol CE < 0 . 05) (Tables I and IV). 
The locomotor activity due to pipradrol seemed to be also 
potentiated with the animals showing signs of extreme 
agitation, leg- thumping and vocalization. 
Effects of Pipradrol in Rabbits Pretreated with a Beta-
Adrenergic Receptor Blocker. 
Pretreatment with propranolol HCl 1.0 mgjkg I.V. 30 
minutes prior to pipradrol HCl 5.0 mgjkg I.V. (Table I) 
had little effect on the hyperthemic response of pipradrol 
(Figure 12). The area- under-the-curve data (Table IV) 
showed no significant CE > 0.05) difference between the 
two curves. However, two of the animals had to be sacri-
ficed due to excessive body temperatures. 
Effects of Pipradrol in Rabbits Pretreated with a Central 
Nervous System Depressant. 
Pentobarbital Na 10.0 mgjkg I.V. given 30 minutes 
before pipradrol HCL 5.0 mgjkg I.V. (Figure 13, Table III) 
--
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had no significant effect (P > 0.05) on the hyperthermic 
capacity of pipradrol (Table V). The effect of pento-
barbital greatly attenuated the locomotor activity, with 
the animals remaining quiescent throughout the experiment. 
A dose of 10.0 mg/kg I.V. is not sufficient to produce 
loss of the righting reflex and barbiturate anesthesia. 
Effects of Clonidine in Rabbits Pretreated with HEAT . 
Clonidine HCl 2.5 mgjkg I.V. (Figure 14) was able to 
produce an increase in the colonic body temperature similar 
in nature to that of pipradrol (Table III). Pretreatment 
with HEAT I.V. 0.5 mgjkg 30 minutes before clo nidine was 
able to completely block (P < 0.05) the hyperthe rmic re-
sponse of clonidine (Figure 14, and Table VI). 
Effects of Apomorphine in Rabbits Pretr eated with Pimozide. 
Apomorphine alone was shown to have hyperthermic 
properties in rabbits (Tabl e II). When given to rabbits 
pretreated with pimozide 4.0 mgjkg (-60 minutes) I.P. at 
a dose of 5.0 mgjkg, the hyperthe rmia was completely 
abolished (Tabl es III and VI). 
Effects of Successive Treatments of Pipradrol . 
There-administration of pipradrol 5.0 mgjkg. I .V . 6 
hours after the initial treatment with pipradrol 5.0 mgjkg 
I.V. showed no significant (~ > 0.05) difference in the 




Table I. Colonic Temperature Effects of Pipradrol in 
Rabbits Pretreated with Various Known Receptor 
Blockers. 
Treatment, Dosage, 






Chlorpromazine HCl I.V. 4 
0.5 mg/kg (-30) 
Chlorpromazine HCl I.V. 5 
1. 0 mg/kg (- 30) 
Haloperidol I.V. 7 
0.5 mg/kg (-30) 
Pimozide I.P. 6 
4.0 mg/kg (-60) 
Phenoxybenzamine HCl I.V. 5 
1. 0 mg/kg ( -60) 
HEAT I.V. 6 
0.125 mg/kg (-30) 
HEAT I. V. 4 
0.25 mg/kg (-30) 
Cinanserin HCl I.V. 6 
5.0 mg/kg (-60) 
-5 Min. Colonic 
Temperature 



















































2. 5 mg/kg 
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Change in Colonic Temperature with Time oc ± SEM 
+15 +30 +45 +60 +75 +90 +10S +120 Min. 
+0.03 -0.10 +0,03 +0.03 +0.03 0.00 0.00 +0.03 
±0.03 ±0.06 ±0.03 ±0.03 ±0.03 ±0.00 ±0.03 ±0.03 
+0.70 +0.90 +1. 00 +1.10 +1.10 +1.10 +1.10 +0.90 
±0.08 ±0.11 ±0.12 ±0.14 ±0.11 ±0.11 ±0.11 ±0.09 
+0.80 +1.20 +1. so +1.60 +1.70 +1. 60 +1. 60 +1. 30 
±0.1S ±0.13 ±0.1S ±0 .13 ±0.1S ±0.17 ±0.20 ±0.22 
+1. 20 +2.80 +3,00 +3.30 
±0.24 ±0.21 ±0.26 ±0.23 
+O.SO +0.80 +1. 00 +1.10 +1.20 +1. 20 +1. 30 +1.30 
±0 . 20 ±0.20 ±0.27 ±0.23 ±0.20 ±0.20 ±0.20 ±0.23 
+0.20 +0.20 +0.20 +0.40 +0.40 +0.40 +0,40 +0.40 
±O.OS ±O.OS ±O.OS ±0.10 ±0.10 ±0.10 ±0.09 ±0.07 
+1. 00 +1.40 +1. 80 +1.90 +2.00 +2.10 +2.00 +2.00 
±0.20 ±0.20 ±0.20 ±0.26 ±0.35 ±0. 30 ±0.40 ±0.40 
+1. 20 +1.50 +1.SO +1.60 +1. 70 +1.70 +1.50 +1. 40 
±0.19 ±0.20 ±0.27 ±0.22 ±0.22 ±0.19 ±0.19 ±0.18 
+0.40 +0.70 +0.80 +0.90 +0.80 +0.80 +0.80 +0.60 
±0.10 ±0.06 ±0.08 ±0.08 +0.12 ±0.13 ±0.12 ±0.12 
+0.40 +0.60 +0.70 +0.80 +0.70 +0.70 +0.70 +0.60 
±0.09 ±0.09 ±0.10 ±0.10 ±0.09 ±0.09 ±0.10 ±0.13 
+0.10 +0.10 +0.10 +0.30 +0.30 +0.40 +O.SO +0.60 
±O.OS ±0.03 ±0.05 ±0.12 ±0.08 ±0.10 ±0 .0 8 ±0.12 
+O.SO +0.80 +0.87 +0.97 +0.88 +1. 08 +1. OS +1. 08 
±0 .09 ±0.10 ±0.16 ±0.21 ±0.16 ±0.16 ±0.15 ±0.15 
continued 
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Table I. (continued) 
Treatment, Dosage, N -5 Min. Colonic Zero-Time 
(Injection Time, Min.) Temperature Challenge 
°C ± SEM Dosage, I. V. 
Cyproheptadine HCl I. V. 7 39.90 Pipradrol HCl 
2. 0 mg/kg (- 30) ±0.29 5.0 mg/kg 
Diphenhydramine HCl I. v. 6 39.70 Pipradrol HCl 
6.0 mg/kg ±0.20 5.0 mg/kg 
Atropine S04 I.V. 4 39.37 Pipradrol HCl 
2.0 mg/kg (- 30) ±0.31 5.0 mg/kg 
Propranolol HCl I. v. 3 39.20 Pipradrol HCl 
1. 0 mg/kg (-30) ±0.20 5.0 mg/kg 
26 
Change in Colonic Temperature with Time oc ± SEM 
+15 +30 +45 +60 +75 +90 +105 +120 Min. 
+1. 28 +1.70 +2.23 +2.45 +2.60 +2.88 +3.03 +3.08 
±0.33 ±0.31 ±0.32 ±0. 30 ±0.28 ±0.35 ±0.47 ±0.47 
+1. 30 +1. 80 +2.20 +2.30 +2.30 +2.10 +1. 90 +1. 90 
±0.20 ±0.14 ±0.12 ±0.20 ±0.20 ±0.30 ±0. 30 ±0.40 
+1. 00 +1. 90 +2.20 +2.30 +2.70 +2.60 +2.70 +2.80 
±0.10 ±0.10 ±0.20 ±0.20 ±0.20 ±0.20 ±0.20 ±0. 30 
+1. 20 +1.90 +2.20 +2. 30 +2.20 +2.30 +2.10 +2.00 






Table II. Colonic Temperature Effects of Pipradrol in 
Rabbits Pretreated by Intracerebroventricular 
Administration of HEAT. 
Treatment, Dosage r.c.v. N -5 Min. Colonic Zero-Time 
(Injection Time, Min.) Temperature Challenge 
°C ± SEM Dosage, I. v. 
Sterile, Pyrogen-Free 4 39.25 Saline 
Normal Saline 100 ( -15) ±0.05 1 ml/kg 
HEAT 4 39.32 Saline 
0.15mg ( -15) ±0.08 1 ml/kg 
HEAT 6 39.12 Pipradrol HCl 
0.15mg (-15) ±0.05 5.0 mg/kg 
28 
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Change in Colonic Temperature with Time oc ± SEM 
-
+15 +30 +45 +60 +75 +90 +105 +120 Min. 
+0.05 +0.13 +0.10 +0.13 +0.08 +0.13 +0.15 +0.20 
±0. 03 ±0.05 ±0.06 ±0.09 ±0.09 ±0.08 ±0.03 ±0.04 
+0.05 +0.05 0.00 +0.05 -0.03 -0.13 -0.15 -0.18 
±0.03 ±0.20 ±0.04 ±0.04 ±0.09 ±0.09 ±0.03 ±0.03 
+0.32 +0.43 +0.40 +0.60 +0.60 +0.60 +0.56 +0.56 







Table III. Effects of Various Drugs and Pretreatments on the 
Colonic Body Temperature of Rabbits. 
Treatment, Dosage, 
(Injection Time, Min.) 
HEAT I. V. 
0.125 mg/kg (-30) 
Pimozide I.P. 
4.0 mg/kg (-60) 
Pentobarbital Na I.V. 
10.0 mg/kg (-30) 
Pipradrol HCl I.V. 









-5 Min. Colonic 
Temperature 





















2. 5 mg/kg 
Apomorphine 
HCl 5.0 mg/kg 
Apomorphine 






Change in Colonic Temperature with Time oc ± SEM 
+15 +30 +45 +60 +75 +90 +105 +120 Min. 
+0.03 -0.10 +0.03 +0.03 +0.03 0.00 0.00 +0.03 
±0.03 ±0.06 ±0.03 ±0.03 ±0.03 ±0.00 ±0.03 ±0.03 
+0.60 +0.70 +0.80 +1.00 +1. 00 +1. 30 +1. 50 +1. so 
±0.00 ±0.03 ±0.05 ±0.06 ±0.12 ±0.14 ±0.14 ±0.15 
-0.20 +0.10 0.00 0.00 -0.10 -0 . 20 -0.30 -0.40 
±0.00 ±0.03 ±0.12 ±0.15 ±0.24 ±0.26 ±0.26 ±0.33 
+0.40 +1.10 +1. so +1. 40 +1. 20 +0.90 +0.80 +0.60 
0.00 0.00 0.00 0.00 0.00 -0.10 -0. 20 -0.10 
+0.60 +1. 00 +1. 30 +1.60 +1. 80 +1.90 +2.10 +2.00 
±0.12 ±0.17 ±0.23 ±0.17 ±0.18 ±0.15 ±0.27 ±0.34 
+0.97 +1.17 +1. 40 +1.40 +1. 40 +1. 30 +1.20 +1. 07 
±0.19 ±0.22 ±0.27 ±0.25 ±0.25 ±0.22 ±0.15 ±0.07 
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Table IV. Evaluation of the Area-Under-the-Curve Data for the Colonic Temperature Effects 
of Pipradrol in Rabbits Pretreated with Various Known Receptor Blockers. 
Treatment, Dosage Challenge N Area Under the p 
(Injection Time, Min.) I.V. Dosage Curve ± SEM 
Saline 3 0.7S ± 0.1 > o.os 
1.0 ml/kg 
Pipradrol HCl 10 17S.S ± 18.6 
S.O mg/kg 
Pipradrol HCl 8 126.4 ± 12.8 <'. o.os 
2.S mg/kg 
Chlorpromazine HCl I.V. Pipradrol HCl 4 124.9 ± 2S.4 <: o.os 
O.S mg/kg (-30) S.O mg/kg 
Chlorpromazine HCl I.V. Pipradrol HCl s 41.8 ± 9.7 < o.os 
1. 0 mg/kg (- 30) S.O mg/kg 
Haloperidol I.V. Pipradrol HCl 7 212.6 ± 32.6 > 0. OS 
O.S mg/kg (-30) S.O mg/kg 
Pimozide I. P. Pipradrol HCl 5 183.6 ± 2S.l > 0. OS 
4.0 mg/kg (-60) S.O mg/kg 
Phenoxybenzamine HCl I.V. Pipradrol HCl 4 8S.l ± 9.1 < 0. OS 
1.0 mg/kg (-60) S.O mg/kg 
HEAT I. V. Pipradrol HCl 6 78.9 ± 10.7 < 0. OS 
0.12S mg/kg (-30) S.O mg/kg 
0 
Table IV. (continued) 
Treatment, Dosage 
(Injection Time, Min.) 
Cyproheptadine HCl I.V. 
2.0 mg/kg (-30) 
Cinanserin I.V. 
S.O mg/kg (-60) 
Diphenhydramine HCl I.V. 
6.0 mg/kg ( -30) 
Atropine so 4 I.V. 2.0 mg/kg ( -30) 
Propranolol HCl I.V. 
1.0 mg/kg ( -30) 
I ' I I ! I ! I 
I I. I I . 1 
-- - ~ I I 
Challenge N Area Under the p 
I. V. Dosage Curve ± SEM 
Pipradrol HCL 
S.O mg/kg 
3 294.7 ± 42.7 <.O.OS 




s 236.2 ± 26.2 >0. OS 
Pipradrol HCl 4 261.3 ± 12.8 <. o.os 
5.0 mg/kg 




I I I II I I I I I I 
I _ _I_ 1 I . ~ 
Table V. Evaluat ion of the Area-Under-the - Curve Data for the Colonic Temperature Effects 
of Pipradrol in Rabbits Pretreated by the Intracerebroventricular Administration 
of HEAT. 
Treatment, Dosage I . C.V. Challenge N Area Under the p 
( I njection Time , Min . ) I. V. Dosage Curve ± SEM 
Sterile, Pyrogen- Free Sal i ne 4 14 . 5 ± 0.1 (. 0. OS 
Normal Saline 100 (-15) 1 m1/kg 
Pipradr ol HC1 10 175 . 5 ± 18 . 6 
5.0 mg/kg 
HEAT Saline 4 -5 . 1 ± 0 . 1 L.. 0.05 
0.15 mg (-15) 1 m1/kg 
HEAT Pipradrol HCl 6 62.0 ± 12.5 <_ 0.05 
0.15 mg ( - 15) 5.0 mg/kg 
w 
w 
; ' _j l ~ : I : 1 I 
Table VI. Evaluation of the Area-Under-the-Curve Data for the Effects of Various 
Drugs and Pretreatments on the Colonic Body Temperature of Rabbits. 
Treatment, Dosage Challenge N Area Under the 
(Injection Time, Min.) I. V. Dosage Curve ± SEM 
Saline 3 0.7S ± 0.1 
1. 0 ml/kg 
Clonidine HCl 3 137.00 ± 3.8 
2. S mg/kg 
HEAT I. V. Clonidine HCl 3 -18.00 ± 6.8 
O.S mg/kg (-30) 2.S mg/kg 
Pipradrol HCl 10 17S.SO "± 18."-6 
S.O mg/kg 
Pentobarbital Na I.V. Pipradrol HCl 3 172.00 ± 22.3 
10.0 mg/kg (-30) S.O mg/kg 
Apomorphine HCl 1 118.SO 
S.O mg/kg 
Pimozide HCl I.V Apomorphine HCl 1 -s.oo 
4.0 mg/kg (-60) S.O mg/kg 
Pipradrol HCl I.V. Pipradrol HCl 3 149.00 ± 18 . S 




> 0. OS 




Figure 1. The Dose Response of the Colonic Body Temperature in Rabbits given Pipradrol. 
0 Pipradrol HCl 2.5 mg/kg I.V. 
X Pipradrol HCl 5.0 mg/kg I.V. 
~ Pipradrol HCl 10.0 mg/kg I.V. 
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Figure 2. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
Chlorpromazine (-30 minutes). 
0 Pipradrol HCl 5.0 mg/kg I.V. 















































Figure 3. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
Haloperidol (-30 minutes). 
0 Pipradrol HCl 5.0 mg/kg I.V. 
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Figure 4. The Colonic Temperature Effects of Pipradrol and Apomorpine in Rabbits 
Pretreated with Pimozide (-60 minutes). 
~ Pipradrol HCl 5.0 mg/kg I.V. 
o Pimozide 4.0 mg/kg I.P. and Pipradrol HCl 5.0 mg/kg I.V. 
























































Figure 5. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
Phenoxybenzamine (-60 minutes). 
0 Pipradrol HCl 5.0 mg/kg I.V. 
































































Figure 6. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
HEAT (-30 minutes). 
0 Pipradrol HCl 5.0 mg/kg I.V. 
~ HEAT 0.125 mg/kg I.V. and Pipradrol HCl 5.0 mg/kg I.V. 
" 
46 















~ ' ~ • f 
I I I 
1 
I 
I {g I 
I + oo I 
~ 
I 
~ I I I I 
I 
1~ I I ~ <0 1'\ 
' z \ 
I H 
' 1:. I v 
' ;~ w \ 




' ' ' ' I {g 




UO~OZHU WOO~ t-W~~ U 
47 
Figure 7. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
HEAT (-15 minutes). 
1::J Pipradrol HCl 5. 0 mg/kg I. V. 
C Saline Vehicle I.C.V. 
~HEAT 0.15 mg r.c.v. 
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--
Figure 8. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
Cinanserin (-60 minutes). 
)(. Pipradrol 2. 5 mg/kg I. V. 
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Figure 9. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
Cyproheptadine (-30 minutes). 
~ Pipradrol HCl 5.0 mg/kg I.V. 
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Figure 10. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
Diphenhydramine (-30 minutes). 
~ Pipradrol HCl 5.0 mg/kg I.V. 
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Figure 11. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
Atropine (-30 minutes). 
~ Pipradrol HCl 5. 0 mg/kg I. V. 
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Figure 12. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
Propranolol (-30 minutes). 
'/. Pipradrol HCl 5. 0 mg/kg I. V. 
0 Propranolol HCl 1.0 mg/kg I.V. and Pipradrol HCl 5.0 mg/kg I.V. 
UO~OZHU ~OCr ~W~~ U 
59 
---~ 
Figure 13. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with 
Pentobarbital (-30 minutes). 
X Pipradrol HCl 5.0 mg/kg I.V. 
0 Pentobarbital Na 10.0 mg/kg I.V. and Pipradrol HCl 5.0 mg/kg I.V. 
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Figure 14. Colonic Temperature Effects of Clonidine in Rabbits Pretreated with 
HEAT (-30 minutes). 
)( Clonidine 2. 5 mg/kg I. V. 
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Figure 15. The Effect of Successive Treatments of Pipradrol on the Colonic Body 
Temperature of Rabbits. 
)( Pipradrol HCl 5.0 mg/kg I.V. 8:00 A.M. 
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The results of this study show that the I.V. admin-
istration of pipradrol causes dose-relat ed hyperthermia in 
the rabbit as wel l as behavioral c hanges characterized by 
both compulsive gnawing and increased locomotor activity. 
Compulsive gnawing was manifested by either grinding 
the teeth or by biting the metal water trough continuously . 
The locomotor activity consisted of signs of tenseness as-
sociated with occasional episodes of l eg-thumping and at-
tempts to escape from the r estraining stanchion . After 
the administration of pipradrol, vasodilation was also ob-
served to occur in t he ear veins with the ears becoming 
very warm to the touch. The ear s are normally cool to 
cold at the ambient temperature of 23° C. 
A dose-response curve was established using I.V. 
doses consisting of 2 . 0, 5 . 0 and 10.0 mgjkg . The dosage 






which was tolerated well by all of the animals tested. 
At the 10.0 mgjkg dosage, death occurred in 50% of the 
tested animals. The cause of death appeared to be respira-
tory failure occurring during tonic-clonic convulsions . 
While the effects of pipradrol appear to parallel 
those effects reported to be seen with amphetamine, there 
are questions as to whether these two drugs are acting by 
the same mechanisms. It has been reported that the be-
havioral excitatory effects of pipradrol are dependent on 
catecholamines stored in a reserpine-sensitive pool while 
those of amphetamine are produced independently of this 
catecholamine source (22). The behavioral action of both 
these drugs, however, ultimately appears to depend on the 
synthesis of catecholamines. There also has been shown 
to be no stereochemical relationship between the more 
active enantiomers of pipradrol and amphetamine in studies 
conducted on rat locomotor activity (53). 
In an effort to investigate the nature of the recep-
tors involved in mediating the responses seen with pipradrol, 
various receptor antagonists were utilized. Chlorproma-
zine, which is known to antagonize alpha-adrenergic, hista-
mine, dopamine and acetylcholine receptors, was found to 
block the hyperthermia seen with pipradrol (Figure 16) 
and this effect was dose-dependent. Chlorpromazine also 
inhibited both compulsive gnawing and locomotor activity and 
the animals generally appeared to be depressed . This effect 
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Figure 16. Comparative Evaluation of Area-Under-The-Curve Data for the Colonic 
Body Temperature Effect of Intravenous Pipradrol in Rabbits Pretreated 
with Various Known Receptor Blockers (bars represent one S.E.M.; dashed 
lines represent the range betweeen the mean + 1 S.E.M. for pipradrol HCl 
5.0 mgfkg I.V.). 
1. Pipradrol HCl 5.0 mgfkg I.V. 
2. Pipradrol HCl 2.5 mgfkg 
3. Haloperidol 0.5 mgfkg I.V. and Pipradrol HCl 5.0 mgfkg I.V. 
4. Pimozide 4.0 mgfkg I.P. and Pipradrol HCl 5.0 mgfkg I.V. 
5. Chlorpromazine HCl 1.0 mgfkg I.V. and Pipradrol HCl 5.0 mgfkg I.V. 
6. Phenoxybenzamine HCl 1.0 mgfkg I.V. and Pipradrol HCl 5.0 mgfkg I.V. 
7. HEAT 0.125 mgfkg I.V. and Pipradrol HCl 5.0 mgfkg I.V. 
8. Cinanserin HCl 5.0 mgfkg I.V. and Pipradrol HCl 2.5 mgfkg I.V. 
9. Cyproheptadine HCl 2.0 mgfkg I.V. and Pipradrol HCl 5.0 mgfkg I.V. 
10. Diphenhydramine HCl 6.0 mgfkg I.V. and Pipradrol HCl 5.0 mgfkg I.V. 
11. Atropine so
4 
2.0 mgfkg I.V. and Pipradrol HCl 5.0 mgfkg I.V. 
12. Propranolol HCl 1.0 mgfkg I.V. and Pipradrol HCl 5.0 mgfkg I.V. 









is in agreement with its clinical utility as a major tran-
quilizer. 
The failure of the dopamine receptor blockers halo-
peridol and pimozide to block pipradrol-induced hyper-
thermia (Figure 16) indicates that, unlike amphetamine, the 
involvement of dopaminergic pathways is not a significant 
component of this response. Haloperidol eliminated the 
incidence of compulsive gnawing caused by pipradrol; how-
ever, pretreatment with pimozide appeared to have little 
effect on compulsive gnawing. Comparison of the tempera-
ture indexes (Figure 16) of haloperidol and pimozide in-
dicates that (at the doses used) haloperidol has slightly 
more influence than ·pimozide on the hyperthermic effect of 
pipradrol. While not statistically significant, the effect 
of haloperidol appeared to potentiate the hyperthermic re-
sponse of pipradrol . 
With I.V. pretreatment with alpha-adrenergic blocking 
agents phenoxybenzamine and HEAT, both were shown to in-
hibit the hyperthermic response to pipradrol (Figure 16). 
These results suggest the involvement of alpha-adrenergic 
receptors in the thermotropic response to pipradrol. The 
alpha-adrenergic component fits the model (Figure 17) pro-
posed by Tang~i et al. (46) which suggests that by stimula-
tion of alpha-adrenergic receptors in the preoptic area of 
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Figure 17. A proposed model for thermoregulation involv-
ing NE (norepinephrine), alpha-adrenergic 
receptors, nicotinic acetylcholine recep-
tors and muscarinic acetylcholine receptors 
(after Tangri E aJ.. ) ( 46) . 
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response is thought to be mediated through nicotinic acetyl-
choline receptors in the caudal hypothalamus. It is also 
suggested that this pathway is mediated through the stimula-
tion of "cold sensitive" receptors. In an effort to estab-
lish the involvement of pipradrol centrally in mediating 
hyperthermia, HEAT was administered I .C .V. 15 minutes prior 
to I.V. pipradrol which resulted in attentuation of the 
hyperthermia (Figure 7). Substances int roduced into the 
lateral cerebral ventricles are known to have ready access 
to the preoptic area of the anterior hypothalamus which is 
thought to be the area involved in temperature regulation 
(60). 
The antihypertensive drug clonidine is known to be 
a potent alpha-adrenergic receptor stimulant in both the 
peripheral and central nervous systems (61). The I.V. 
administration of clonidine was shown to cause a hyper-
thermic response (similar to that seen with pipradrol) which 
was inhibited by pretreatment with HEAT administered I .V. 
These data give evidence that in the rabbit HEAT is capable 
of inhibiting hyperthermia induced by a known alpha-
adrenergic stimulant. The pretreatment with HEAT I.V. also 
appeared to attenuate the locomotor activity seen with pip-
radrol but an increase in compulsive gnawing was observed. 
These observations are in conflict with those reported by 
Clineschmidt (53) whose findings showed an inhibition of 
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apomorphine-induced gnawing in the mouse indicating antagon-
ism of central dopaminergic receptors. 
The I.V. pretreatment with the serotonergic receptor 
blocker cyproheptadine resulted in a significant CR < 0.05) 
potentiation of the hyperthermia seen with pipradrol. The 
animals were extremely agitated during the course of the 
experiment and three of the six animals had to be sacrificed 
due to excessive body temperatures (> 44° C). Since cypro-
heptadine has antihistaminic and weak anticholinergic 
activity as well as antiserotonin properties, it was not 
clear as to which of these actions is responsible for the 
potentiation. However, information collected later in 
this study showed that while the antihistamine diphen-
hydramine also appeared to elevate the hyperthermic response 
to pipradrol, this response was not significant (P > 0.05). 
These results tend to indicate that the potentiation of 
hyperthermia may reside within the antiserotonin or anti-
cholinergic capabilities of cyproheptadine. These results 
agree with the thermoregulatory model presented by Tangri 
et al. (46) which suggests a role for serotonin in mediating 
hypothermia through muscarinic receptors in the rabbit 
(Figure 17). Inhibition of these serotonin receptors 
would impair the "heat sensitive" mechanism for thermo-
regulation, thus allowing for uninhibited hyperthermia to 







a significant block of the thermic response to pipradrol. 
However, this may be dose-dependent and higher doses of 
cinanserin could produce different results. 
The hyperthermic effect of pipradrol was not signifi-
cantly altered by pretreatment with the antihistaminic 
compound diphenhydramine. This effect appeared to be slight-
ly potentiated but was not statistically significant <E > 
0 . 05). Diphenhydramine also possesses anticholinergic 
activity and it may be this component which is responsible 
for the tendency for potentiation of the pipradrol-induced 
hyperthermia. 
The anticholinergic agent atropine has high affinity 
for the muscarinic receptor and very little for the nico-
tinic receptor. Pretreatment with atropine resulted in 
a significant (P < 0.05) potentiation of the pipradrol-
induced hyperthermia. These results also agree with the 
model (Figure 17) proposed by Tangri et al. (46). It is 
suggested that the muscarinic receptor which is "down-
stream" from the serotonin receptor is also associated 
with the thermoregulatory process -- more specifically 
with the mediation of hypothermia due to stimulation of 
"heat-sensitive" receptors. It may be that blockade 
of either muscarinic receptors or serotonin receptors 
would result in inhibition of the compensatory mechan-
ism involved in controlling the hyperthermic response 




effect. The pretreatment with atropine also appeared to 
potentiate the locomotor activity due to pipradrol. It 
is not clear as to the nature of involvement of muscarinic 
receptors in mediating locomotor activity in the rabbit. 
The involvement of the beta-adrenergic receptor in 
the mediation of hyperthermia by pipradrol was studied 
by pretreatment with the beta-adrenergic blocker proprano-
lol. The failure of propranolol to influence the thermic 
response of pipradrol suggests that these receptors are 
not closely associated with this event. The work of 
Dhawan and Dua (31) also failed to substantiate a basis 
for the involvement of beta-adrenergic receptors in the 
hyperthermia associated with norepinephrine. 
Pipradrol has been shown to cause excitation and 
increased locomotor activity in the rabbit. To investi-
gate whether or not this activity influences the body 
temperature of rabbits treated with pipradrol, the cen-
tral nervous system depressant pentobarbital was given as 
an I.V. pretreatment at a dose which rendered the animals 
quiescent but not anesthetized throughout the experiment. 
The failure of pentobarbital to influence the hyperthermia 
seen with pipradrol (Figure 16) suggests that this effect 
is not directly related to excessive locomotor activity or 
to excitation. However, this does not rule out a peripheral 
component of hyperthermia since pentobarbital is known to 
75 
act only centrally in its depressant action. 
It has been stated many times that "no drug has a 
single effect." The events presented in this study rep-
resent only a small window in the vast picture of the 
possible pharmacological activities of pipradrol. 
CONCLUSIONS 
From this study it can be concluded that there is a 
characteristic dose-related hyperthermia produced in re-
sponse to I.V . administered pipradrol. This thermotropic 
activity may be associated with different neuronal recep-
tors, the most important of which appears to be alpha-
adrenergic in nature. The antagonism of hyperthermia by 
the alpha-adrenergic blockers HEAT (administered both 
peripherally and centrally), chlorpromazine and phenoxy-
benzamine lends support for an alpha-adrenergic mechanism 
which is at least in part centrally mediated. 
The failure of dopamine receptor blockers haloperidol 
and pimozide to attenuate the hyperthermia seen with pip-
radrol suggests that dopaminergic pathways are not direct l y 
involved in this response. These data indicate a di ffe r-
ent thermotropic mechanism of action for pipradrol than t he 








thought to mediate hyperthermia in the rabbit via dopamin-
ergic pathways. 
The results of this study also give support for the 
controversial thermoregulartory model proposed by Tangri 
et al. (46), since both the antiserotonin drug cyprohepta---
dine and anticholinergic drug atropine potentiate pipra-
drol's hyperthermic activity. 
The involvement of beta-adrenergic receptors has been 
shown to be not significant in this study . 
Histamine receptors which have been shown to be thermo-
tropic in other species have not been shown to be unequi-
vocally significant or not significant in this study. Fur-
ther work will be needed to allow a definite statement to 
be made . 
The more apparent behavioral components of pipradrol 
administration consist of increased locomotor activity and 
compulsive gnawing. These may be produced by two different 
mechanisms as evidenced by the attenuation of locomotor 
activity and potentiation of compulsive gnawing by the 
administration of HEAT. Since these behavioral aspects 
of pipradrol were not statistically evaluated, this con-
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APPENDIX A 
CALCULATION OF AREA UNDER THE CURVE 
The area-under-the-curve data (A) was calculated using 
a TI-58C hand-held calculator . 
A = 
[S (6t I)1 + S (6t I) 2 ... + S (6t I)N] 
N 
S = sum of 
6t = change in temperature (degrees, centigrade) 
I= time interval (15 min.) 
N = test group number 
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420 URITELN I' OR ER RORS UILL RESULT IN THE T-VALUES TH AT ARE GENERATED \ 
\ . •') ; 
430 URlTE LN; 
44 0 URITELN; 
450 
460 <* READ IN CONTROL VALUES *l 
470 1 :URITELNI ' ENTER THE TOTAL NUMBER OF GROU PS. ' I; 
480 READ INUMGRP I ; 
490 URITELN; 
500 URITELN I' ENTER THE NUMBE R OF VALUES OF THE CON TROL GR OUP . ' ! ; 
510 READINUMI; 
520 URITELN; 
530 URITELNI ' ENTER THE VALUES.'!; 




580 NGRP{1J:= NUM; 
590 IJRITELN; 
600 
610 (* READ IN EXPERIMENTAL VALUES *l 
620 FOR J:= 2 TO NUMGRP DO 
630 B£GIN 
640 NAP:= J - 1 ; 
650 IJRITELN I ' ENTER THE NUMBER OF VALUES OF EXPERIMENTAL GROUP ' ,NAP\ 
\ :2>; 
660 READ INUM J; 
670 l.JRITEU~; 
680 URITELN !' ENTER THE VALUES. ' ) ; 
690 FOR I:= 1 TO NIJM DO 
700 BEGIN 
710 RE ADIVALUE[I,JlJ; 
?20 END; 
730 NGRP( J l:= NUM; 
7 40 UR ITELN; 
750 END; 
760 
770 I* CALCULATE TOTAL NUMBER OF VALUES * I 
780 NTOT:= o; SX2T:= o; SSG:= O; TX T:= O; 
790 FOR J: = 1 TO NUNGRP DO 
800 BEGIN 
810 TX:= o; SX2:= O; 
820 NTOT: = NTOT + NGRP(JJ; 
830 
840 I* CAL CU LATE TOTAL OF VALUES AND SQUARED VALUE S *I 
8~0 FOR I:= 1 TO NGRP[ JJ DO 
86 0 BEGTii 
870 TX : = TX t VALUE(I,Jl; 






















































SX2:= SX2 • SOR!VALUEEI,JJ J; 
SX2T:= SX2T + SOR!UALUECI,JJJ; 
END; 
SSG := SSG • SGRITXI / NGRPCJJ; 
XGR P[JJ:= TX / HGRPCJJ; 
86 
SENCJJ:= SQRT!( SX2-ISQR( TXI/HGRP[J Jll /( NGRP[JJ ·· 11 1/SQRT(NGRP[JJ \ 
\ ) ; 
END; 
I* CALCULATE C A~D FINAL SSG *l 
C:= SOR!TXTJ / NTOT; 
SSGFIN:= SSG - C; 
!* CALCU LA TE F VALUES *l 
DFBETGRP := NUNGRP - 1; 
DFUTHGRP: = NTOT - NUMGRP; 
MEANSOUARE:= SSGFIN/DFBETGRP; 
52:= ISX2T - C - SSGFINl/DFUTHGRP; 
F:= MEANSGUARE /52 ; 
FG:= NTOT/NUMGRP; 
SD:= SGRT<2*S2/FG>; 
l.IR I T-ELN < ·' * '~*'~'*"' * '~* '~ '~***** '~* * '~**'~********* '~ *'"*'1'***'1'* '1' "' 'r.**** * ***'~ .-'.. 
\ ); 
URI TELN I ' ********** '~<*** '~** * '~* '~*=•*****:t * :~: :~::t:** '~ ***** '~ ***'~*'~*'~<* '"* ' r. ·' \ 
\ ) ; 
URITELN; 
IJR.ITEUH ·' THE D.F. BETUEEN GROUPS= ·' ,DFBETGRP:41; 
IJR i TEU~; 
IJR ITEU~ <·' THE D. F. 1.1 ITH IN GROUPS = .. , L:F\.ITHGRP: 4 I ; 
URITELN; 
lJ R IT E L N < ·' THE F- VALUE I 5 ·' ~ r- : 1 1 : -4 i ; . 
URITELN; 
P l.IRITE THE 









S . E .M. 
FOR THE CONTROL :t.) 
FOR THE CONTROL GROUP: ' ) ; 
= ' ,NGRPC1J:11 >; 
= -' ,XGRPC1J:II:41; 
= ~,SEM[1l:11:4 l ; 
I* CALCULATE THE DUNNETT ' S T VALUES AN D IJRI TE THE VALUES FOR THE 
EXPERIMENTAL GROUPS *l 
FOR J:= 2 TO NUMGRP DO 
BEGIN 
TVALUE[JJ:= (XGRPC1 J-XGRP(JJ l/SD; 
AN::: J - 1; 




\JF:I TEUH .. 
IJRITELN; 
END; 
VALUES FOR EXPER IMEN TAL GROUP 
N = -' ,NGRPCJJ:l 11 : 
MEAN = ·· , XGRP [ J] : 1 ~ :4 ) : 
S.E.M . = ' ,SEM[JJ : ll :4 ! : 
f - 1lALUE = ·· ,T'v' ALUECJJ:1 1:41; 
.·· ,Ml:2, ·· : ·· :• ; 
87 
1410 
1420 URITELN C' *********************************'~***********~******* ~ l ; 
1430 URITELNC ' ******************~***** * ******* '~******~************* ~ l; 
~ 440 URITELN; 
1450 
1460 <'ASK USER IF HE / SHE WANTS TO GO AGAIN*) 
1470 WRITELH C' DO YOU UISH TO DO ANOTHER DUNNETT''S T- TEST? ' l; 
1480 READ<CH>; 
1490 UHILE CH = ' ' DO READ <CH>; 




1540 GOTO 1; 
1550 END; 
1560 





~END SESSION 7168 ET=5:5t.8 PT=1.2 I0=0.2 
#USER = H00182801 15:39:50 03/19/83 
#B6700:4t7 CANDE 31.280; YOU ARE ACAD/3(23) 
#ENTER USERCODE PLEASE 
H00182701 
#ENTER PASSWORD PLEASE. 
HOB8B888BOOOBBOOO 
#SESSION 7208 15:40:44 03/ 19/83 
GET DUNNETTS;R; FILE INPUT<KIND=DISK,TITLE=STEVE I 
#UORKFILE DUNNETTS: SEG, 157 RECORDS, SAVED 
#OBJECT FILE PRESENT, SAVED 
#RUNNING 7211 
NOTE: THE MAXIMUM NUMBER OF GROUPS THAT THIS PROGRAM 
CAN HANDLE IS 20. THE MAXIMUM NUMBER OF MEASUREMENTS 
WITHIN EACH GROUP IS 30. DO NOT EXCEED THESE LIMITS 
OR ERRORS UILL RESULT IN THE T-VALUES THAT ARE GENERATED. 
ENTER THE TOTAL NUMBER OF GROUPS. 
ENTER THE NUMBER OF VALUES OF THE CONTROL GROUP. 
ENTER THE VALUES. 
ENTER THE NUMBER OF VALUES OF EXPERIMENTAL GROUP 
ENTER THE VALUES. 
88 
THE VALUES 1-0H EXPERIMENTAL Gr;:our-· 1: 
-· N = .., ·' 
MEAN ·- 21 3 . 6429 
: . E. M. :: 32.5881 
T -'JALUE = -0.859} 
-- - fHE t) ALUES f-OR EX F' EIUM ENTAL GROUP 2: 
N = 4 
MEAN = 124 . 8750 
S .E.M. = 25 .3922 
T-'J ALUE = 1. 8451 
r HE VALUES r-:m EXF'EF: I MENTAL GROUP 3: 
N = r=' .J 
MEAN = 41.8000 
S.E.M . = 9. 7386 
T-VALUE = 4.3765 
THE VALUES f-OR EXPERIMENTAL GROUP 4: 
N = r=' ..J 
MEAN = 183.6000 
S.E.M. = 25.1189 
T -VALU( = 0.0558 
THE VALU ES FOR EXPERIM ENTAL GROUP 5: 
N = 4 
MEAN = 85.1250 
S.E.A. = 9.0907 
T-!JALUE = 3 . 0563 
THE VALUES FOR EXPERIMENTAL GR OUP 6 : 
tl = 6 
MEAN :: 78 . 9167 
S . E.M. = 10 . 6571 
T-V ALUE = 3.2455 
THE VALUES FOR EXf-' Ef.: I MENTAL GROUP ..,, / . 
N = 3 
MEAN = 172.5000 
S.E.M . = 22.6991 
T-VALUE = 0 . 3940 
THE VALUES FOR EXPERIMENTAL GROUP 8: 
N = 6 
MEAN = 110.0000 
S.E.M . = 16 .0888 
T-VALUE = 2 . 2984 
THE VALUES FOR EXPERIMENTAL GRO UP 9: 
II = 4 
MEAN = 261 . 2500 
s.:: .M. :: 12 . , ·S3~ 
T ·-VALUE = -2.3 103 
ENTER THE NUMBER OF VALUES OF EXPERIMENTAL GROUP 2 
ENTER THE VALUES. 
ENTER THE NUMBER OF VALUES OF EXPERIMENTAL GROUP 3 
ENTER THE VALUES. 
ENTER THE NUMBER OF VALUES Of EXPERIMENTAL GROUP 4 
ENTER THE VALUES. 
ENTER THE NUMBER OF VALUES OF EXPERIMENTAL GROUP 5 
ENTER THE VALUES. 
ENTER THE NUMBER OF VALUES OF EXPERIMENTAL GROUP 6 
ENTER THE VALUES. 
ENTER THE NUMBER OF VALUES OF EXPERIMENTAL GROUP 7 
-
ENTER THE VALUES. 
ENTER THE NUMBER OF VALUES OF EXPERIHENTAL GROUP 8 
ENTER THE VALUES • . 
ENTER THE NUHBER OF VALUES Of EXPERIMENTAL GROUP 9 
ENTER THE VALUES. 
ENTER THE NUMBER Of VALUES OF EXPERIMENTAL GROUP 10 
ENTER THE VALUES. 
ENTER THE NUMBER OF VALUES OF EXPERIMENTAL GROUP 11 
ENTER THE VALUES. 
*~*****~***~****************************************** 
*********************************~******************** 
THE D.F. BETUEEN GROUPS = 11 
THE D.F. YITHIN GROUPS = 51 
THE F-VALUE IS 10.380~ 
THE VALUES FOR THE CONTROL GROUP: 
N = 10 
"EAN = 185 . 4300 
S.E.M. = 16.4862 
8 9 
---- -
THE VALUES FOR EXPERIMENTAL GROUP 1 0: 
N = 1:" ..J 
MEAN = 236.2000 
S.E.M. = 26.2172 
T- VALUE = -1.5470 
THE VALUES FOR EXPE RIMENT AL GROUP 11 : 
N : 4 
MEAN = 294.7500 
S.E.M. : 42.7368 
T-V ALUE : -3.3310 
***************************************************** 
***************************************************** 
DO YOU UISH TO DO ANOTHER DUNNETT ' S T- TEST' 
ltET=2:30.1 PT=1.4 !0=1 .0 
GET STEllE; L 
~~ORKFILE STEVE: DATA, 26 RECORDS, SAVED 
100 12 
200 10 
300 1] 5.8 157 .5 159 154.5 268.5 180 120 204 153 282 
400 7 
500 199.5 316.5 316.5 234 97.5 117 214.5 
600 4 
700 60 117 141 181 • 5 
800 ~ 
900 ~ 18 72 56 30 
1000 5 
1100 185 249 221 104 159 
1200 4 
1300 103.5 73 .5 66 97.5 
1400 6 
1500 115.5 63 84 71 42 98 
1600 3 
1700 139.5 162 216 
1800 6 










284 282 234 245 
5 
267 285 150 278 201 
4 
309 250.5 408 211.5 
N 
!tEND SESSION 7208 
ltUSER = H00182701 
ET=4:01.5 PT=1.7 I0=1.0 
15:44:46 03/19 / 83 
90 
